Preliminary evaluation of EVP 1001-1: a new cardiac-specific magnetic resonance contrast agent with kinetics suitable for steady-state imaging of the ischemic heart

Invest Radiol. 2003 Oct;38(10):642-52. doi: 10.1097/01.rli.0000077057.88108.3f.


Rationale and objectives: To investigate the potential of a novel manganese-based magnetic resonance (MR) contrast agent, EVP 1001-1 for the evaluation of myocardial ischemia.

Methods: MR imaging with EVP 1001-1 was performed on 6 Yorkshire pigs, and T1 relaxation times were calculated. One animal served as a control, 2 were subjected to an acute coronary artery occlusion and 3 provided a model of chronic ischemia.

Results: Administration of the agent in the control and acute coronary occlusion model demonstrated a short plasma half-life (approximately 1.5 minutes) and rapid myocardial uptake in nonoccluded regions, with long retention times in the myocardium (>1 hour) and no evidence of redistribution. In the chronic ischemia model, differential enhancement was observed between normal and ischemic tissue, particularly under dobutamine-induced stress.

Conclusions: These properties suggest the use of EVP 1001-1 for steady-state imaging of myocardial perfusion. Contrast administration could be performed under stress conditions outside the scanner, with high-resolution MR images reflecting the stress condition acquired after the stress has subsided.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Contrast Media / pharmacokinetics*
  • Drug Evaluation, Preclinical
  • Magnetic Resonance Imaging / methods*
  • Manganese / blood
  • Manganese / pharmacokinetics*
  • Models, Animal
  • Myocardial Ischemia / diagnosis*
  • Myocardial Ischemia / metabolism
  • Myocardium / metabolism
  • Swine


  • Contrast Media
  • EVP 1001-1
  • Manganese